Detalles de la búsqueda
1.
Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability.
Ann Oncol
; 34(8): 703-713, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37269904
2.
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Cancer Immunol Immunother
; 72(6): 1881-1890, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36690799
3.
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
Ann Oncol
; 33(6): 628-637, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35306156
4.
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
Ann Oncol
; 31(7): 921-929, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32294529
5.
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Cancer Immunol Immunother
; 72(6): 1891-1892, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36847863
6.
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
Ann Oncol
; 28(5): 1036-1041, 2017 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28453692
7.
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
Ann Oncol
; 28(5): 1078-1083, 2017 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28327934
8.
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Ann Oncol
; 27(3): 417-23, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26646759
9.
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
Ann Oncol
; 26(10): 2085-91, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26272806
10.
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Ann Oncol
; 26(8): 1734-40, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25939894
11.
Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929.
Ann Oncol
; 31(9): 1276, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32653357
12.
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Br J Cancer
; 110(5): 1148-54, 2014 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24407191
13.
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.
Ann Oncol
; 25(2): 409-15, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24368400
14.
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Ann Oncol
; 24(9): 2342-9, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23852309
15.
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.
Invest New Drugs
; 31(3): 724-33, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22996801
16.
Twelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented data.
ESMO Open
; 8(1): 100773, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36634532
17.
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Chemotherapy
; 58(5): 371-80, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23235319
18.
11 ESMO 2021 breakthroughs: practicing oncologist's perceptions on data presentation.
ESMO Open
; 7(1): 100376, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35051788
19.
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
ESMO Open
; 7(2): 100418, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35227966
20.
Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.
Br J Cancer
; 104(3): 413-8, 2011 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21245868